Travere Therapeutics, Inc. (TVTX) Market Cap & Valuation Ratios
Travere Therapeutics, Inc. (TVTX) has a market cap of $4.7B and a price-to-sales ratio of 8.0, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TVTXTravere Therapeutics, Inc.Follow TVTX — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| TVTX | 4.7 | — | 8.5 | 219.5 | 2.0% | +77% | -7% | -8% |
| ORKA | 5.3 | — | — | — | -1.9% | — | — | -28% |
| MIRM | 5.2 | — | 8.9 | — | -4.4% | +44% | -135% | -224% |
| PTCT | 5.1 | — | 3.4 | 18.9 | -0.8% | -43% | 12% | — |
| SRRK | 5.1 | — | — | — | -5.9% | — | — | -568% |
| ERAS | 5.0 | — | — | — | -1.9% | — | — | -97% |
| DFTX | 4.8 | — | — | — | -3.5% | — | — | -92% |
| CRSP | 4.8 | — | 223.8 | — | -7.8% | -65% | — | -30% |
| GOSS | 4.7 | — | 87.7 | — | -3.5% | +32% | -312% | — |
| DNTH | 4.3 | — | — | — | -3.6% | -61% | — | -32% |
| EWTX | 4.3 | — | — | — | -3.7% | — | — | -48% |
| Median of these 10 | — | 48.3 | 18.9 | -3.6% | -43% | -135% | -70% |
; EV/Sales 8.5 vs. 48.3.
Growth vs. price
each dot a company · hover or tap for valuesTravere Therapeutics, Inc. — questions
- What is Travere Therapeutics, Inc.'s market cap?
- $4.7B.
- What is Travere Therapeutics, Inc.'s price-to-sales ratio?
- 8.0.
Every figure on this page comes from Travere Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.